Alimera Sciences (ALIM) 2.61 $ALIM
5 Stocks Under $10 Set to Soar
at The Street - Thu Oct 08, 11:13AM CDT
These stocks trading for less than $10 a share are within range of triggering breakout trades.
ONE: 2.30 (+0.07), VTL: 4.57 (-0.05), ALIM: 2.61 (+0.04), LOOK: 0.63 (-0.01), NVIV: 8.81 (+0.47), ESI: 3.80 (+0.01), NPTN: 7.17 (-0.04), DXM: 0.19 (unch)
Alimera Sciences Limited Announces Availability Of Review Paper On Real World Experience With ILUVIEN®
PR Newswire Europe - Mon Sep 28, 6:30AM CDT
Paper highlights 28 cases in the United Kingdom and Germany
ALIM: 2.61 (+0.04)
Alimera Sciences Limited Announces ILUVIEN® Study Results Presented At 15th Euretina Congress
PR Newswire Europe - Thu Sep 24, 6:30AM CDT
Interim six-month data confirms ILUVIEN was well tolerated and effective in reducing retinal thickness and increasing best corrected visual acuity
ALIM: 2.61 (+0.04)
Alimera Sciences enters into exclusive distributor agreement for ILUVIEN in Italy, San Marino and Vatican City
M2 - Fri Aug 14, 5:30AM CDT
Pharmaceutical company Alimera Sciences (NasdaqGM:ALIM) Thursday launched an exclusive agreement for the distribution of ILUVIEN in Italy, San Marino and Vatican City.
ALIM: 2.61 (+0.04)
Alimera Sciences Limited Signs Exclusive ILUVIEN® Distributor for Italy, San Marino and Vatican City
PR Newswire - Thu Aug 13, 7:00AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Alimera Sciences Limited, its European subsidiary based in London, has signed an exclusive five-year agreement with Societa Industria Farmaceutica Italiana S.p.A. (SIFI), headquartered in Catania, Italy, for distribution of ILUVIEN® in Italy, San Marino and Vatican City. Under the terms of this agreement, SIFI will handle all promotion, marketing and commercial activities in those locations for ILUVIEN, Alimera's sustained release intravitreal injection for the treatment of diabetic macular edema.
ALIM: 2.61 (+0.04)
Alimera Sciences reports 2Q loss
Automated Insights - Mon Aug 10, 5:21PM CDT
ALPHARETTA, Ga. (AP) _ Alimera Sciences Inc. (ALIM) on Monday reported a second-quarter loss of $8.6 million, after reporting a profit in the same period a year earlier.
ALIM: 2.61 (+0.04)
Alimera Sciences Reports Second Quarter 2015 Financial Results
PR Newswire - Mon Aug 10, 3:06PM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the second quarter ended June 30, 2015.
ALIM: 2.61 (+0.04)
Sustained Release Ocular Drug Delivery Systems, 2015 - 2025
M2 - Wed Aug 05, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g2gzr3/sustained_release) has announced the addition of the "Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)" report to their offering. The Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)' report provides an extensive study of the emerging market of implants and particulate drug delivery systems (DDS) for ophthalmic diseases. The focus of this study is on commercial implants and those under development, their applications and the likely mid-term and long-term evolution. It is widely anticipated that such drug delivery systems have tremendous potential as they provide improved retention time compared to topical applications and offer convenience over regular intravitreal injections, mainly for posterior eye diseases. The report covers various aspects such as technological progress, product pipeline, target indications, industry and academic research programs to assess new evolving opportunities. We have provided a competitive spider web analysis to compare different implants based on technical parameters (drug elution rate, amount of drug delivered, life of implant etc.) and their likely user friendliness. Our opinion and insights, presented in this study, were influenced by the discussions that we conducted with different ophthalmic implant developers in this industry. The base year for the report is 2014. The report provides market forecasts for the following two time horizons: 2015 - 2020 and 2020 - 2025. In addition to the above, we have also provided our own independent perspective on the key drivers behind the growth of this market, likely challenges and potential threats. The research, analysis and insights presented in this report include the sales potential of various marketed and late stage pipeline ocular sustained drug delivery systemsbased on the current expected launch timelines, adoption rates and the estimated end-use price points.The figures mentioned in this report are in USD, unless otherwise specified. Highlights: - More than 25 companies are currently working on developing sustained release drug delivery systems for the treatment of ocular indications. Examples of some key players include pSivida, Allergan, Ocular Therapeutix, Neurotech Pharmaceuticals, Icon BioScience and GrayBug. - Vitrasert, launched in 1996, was the first ocular implant. It was, however, taken off the market in 2013. Only three more implants have received regulatory approval since 1996; these are Retisert, Ozurdex and Iluvien. - Majority of the systems (52%) are in preclinical stage of development. Over 10 systems are currently undergoing late stage clinical trial studies. Once approved, these inserts are likely to provide a major impetus to the overall market. - DME and Uveitis will provide the much needed boost to the sustained release ocular drug delivery systems market in the short-term. In the mid to long term, the growth will be fostered by launch of sustained release systems for glaucoma and AMD. In fact, more than 15 sustained release formulations are under development for the treatment of glaucoma. - Interest of venture capital firms, licensing/ partnership opportunities will continue to act as key growth drivers of this market. During our research, we identified several instances where venture capitalists and other strategic investors have actively supported the research efforts. - The overall market is likely to be more than USD 6.5 billion in the coming decade. The opportunity could be much higher in the outer years, especially driven by the regulatory approval of implants for delivery of biologics. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Market Overview 5. Product Profiles and Sales Forecast 6. Company Profiles 7. Venture Capital Support 8. Recent Partnerships 9. SWOT Analysis 10. Interview Transcripts 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List Of Companies Companies Mentioned - Partial List of Companies - 3i Plc - AbbVie - Abell Foundation - Aciont, Inc. - Actavis Plc - Aerie Pharmaceutical - Ain Shams University, Cairo, Egypt - Alcon - Alimera Sciences - Allergan - Alliance Medical Products Inc - Alpha Associates - Amgen Inc. - Amorphex Therapeutics - Apax Partners - Ascension Health Ventures - Atlas Venture - Auritec Pharmaceuticals - Avida Group - Bausch & Lomb - Baxter Venture - Bayer Healthcare - BCN Peptides - Ben Venue Laboratories - BioLight Israeli Life Sciences Investments Ltd. - Brandon Biosciences - Brecon Pharmaceuticals Ltd - Brown Advisory For more information visit http://www.researchandmarkets.com/research/g2...ed_release
AGN: 274.84 (-1.32), ALIM: 2.61 (+0.04), AMGN: 149.59 (-0.31), OCUL: 16.34 (+0.87)
Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results
PR Newswire - Thu Jul 30, 7:30AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its second quarter fiscal year 2015 financial results after the market close on Monday, August 10, 2015. An investor conference call will follow on the same day at 4:30 p.m. ET.
ALIM: 2.61 (+0.04)
Alimera Sciences enters into Canadian distribution agreement for ILUVIEN with Knight Therapeutics
M2 - Wed Jul 22, 5:08AM CDT
Pharmaceutical company Alimera Sciences (NasdaqGM:ALIM) revealed on Tuesday the launch of an exclusive agreement for the distribution in Canada of its sustained release intravitreal implant for the treatment of diabetic macular edema, ILUVIEN.
ALIM: 2.61 (+0.04)
Alimera Sciences Signs Knight Therapeutics as Exclusive ILUVIEN(R) Distributor for Canada
Marketwired - Tue Jul 21, 7:02AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"
, a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has signed an exclusive agreement with Knight Therapeutics Inc. (TSX: GUD) ("Knight" , a leading Canadian specialty pharmaceutical company, for the distribution in Canada of ILUVIEN(R), Alimera's sustained release intravitreal implant for the treatment of diabetic macular edema. Under the terms of this agreement, Knight will also handle all regulatory and commercial activities for ILUVIEN in Canada. ILUVIEN currently is not approved for sale in Canada.
ALIM: 2.61 (+0.04), GUD.TO: 7.14 (-0.02)
Alimera Sciences Signs Knight Therapeutics As Exclusive ILUVIEN® Distributor For Canada
PR Newswire - Tue Jul 21, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera" , a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has signed an exclusive agreement with Knight Therapeutics Inc. (TSX: GUD) ("Knight" , a leading Canadian specialty pharmaceutical company, for the distribution in Canada of ILUVIEN®, Alimera's sustained release intravitreal implant for the treatment of diabetic macular edema. Under the terms of this agreement, Knight will also handle all regulatory and commercial activities for ILUVIEN in Canada. ILUVIEN currently is not approved for sale in Canada.
ALIM: 2.61 (+0.04), GUD.TO: 7.14 (-0.02)
Dry (Atrophic) Macular Degeneration Therapeutics Pipeline Review, H1 2015 - 20 Companies & 29 Drug Profiles
M2 - Thu Jul 09, 9:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d36tg9/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Bioheart, Inc. - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Eleven Biotherapeutics Inc. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - Sun Pharma Advanced Research Company Ltd. Drug Profiles - AdipoCell - APL-2 - avacincaptad pegol sodium - EBI-028 - eculizumab - emixustat hydrochloride - fluocinolone acetonide - Gene Therapy for Ocular Diseases - GS-020 - GSK-933776 - HMR-59 - ICR-14967 - lampalizumab - MA09-hRPE - MC-1101 - methotrexate - minocycline Gel - NM-9405 - NT-501 - OpRegen - OpRegen Plus - RC-1 Alpha - Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - RST-001 - Small Molecules for Age Related Macular Degeneration - Small Molecules for AMD - Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - TT-231 For more information visit http://www.researchandmarkets.com/research/d3...y_atrophic
OCAT: 4.70 (+0.02), OPHT: 42.73 (+0.20), FOMX: 6.84 (+0.17), GSK: 40.22 (+0.06), ALIM: 2.61 (+0.04), ALXN: 161.08 (-3.23)
Alimera Sciences To Present At Cantor Fitzgerald Inaugural Healthcare Conference
PR Newswire - Mon Jun 29, 3:05PM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Rick Eiswirth, Chief Operating Officer and Chief Financial Officer, will present at the 2015 Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 at 8:00 a.m. ET at Le Parker Meridien Hotel in New York.
ALIM: 2.61 (+0.04)
BUYINS.NET: INTX, FIBK, PTM, BIP, AGNC, ALIM Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri May 29, 7:56AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Intersections Inc (NASDAQ:INTX), First Interstate Bancsystem Inc (NASDAQ:FIBK), Platinum Group Metals Ltd (NYSE
TM), Brookfield Infrastructure Partners LP (NYSE:BIP), American Capital Agency Corp (NASDAQ:AGNC), Alimera Sciences Inc (NASDAQ:ALIM) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
INTX: 2.01 (+0.06), ALIM: 2.61 (+0.04), BIP: 40.31 (unch), AGNC: 19.36 (-0.08), FIBK: 27.88 (-0.30), PTM: 10.56 (+0.37), PLG: 0.31 (+0.03)
Alimera Sciences Announces Presentation Time Change At UBS Global Healthcare Conference
PR Newswire - Mon May 18, 3:22PM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced a change in the Company's presentation time at this week's UBS Global Healthcare Conference in New York.
ALIM: 2.61 (+0.04)
Alimera Sciences To Present At UBS Global Healthcare Conference
PR Newswire - Mon May 11, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its management will present at the UBS Global Healthcare Conference in New York.
ALIM: 2.61 (+0.04)
5 Stocks Under $10 Set to Soar
at The Street - Thu Oct 08, 11:13AM CDT
These stocks trading for less than $10 a share are within range of triggering breakout trades.
ONE: 2.30 (+0.07), VTL: 4.57 (-0.05), ALIM: 2.61 (+0.04), LOOK: 0.63 (-0.01), NVIV: 8.81 (+0.47), ESI: 3.80 (+0.01), NPTN: 7.17 (-0.04), DXM: 0.19 (unch)
Alimera Sciences Limited Announces Availability Of Review Paper On Real World Experience With ILUVIEN®
PR Newswire Europe - Mon Sep 28, 6:30AM CDT
Paper highlights 28 cases in the United Kingdom and Germany
ALIM: 2.61 (+0.04)
Alimera Sciences Limited Announces ILUVIEN® Study Results Presented At 15th Euretina Congress
PR Newswire Europe - Thu Sep 24, 6:30AM CDT
Interim six-month data confirms ILUVIEN was well tolerated and effective in reducing retinal thickness and increasing best corrected visual acuity
ALIM: 2.61 (+0.04)
Alimera Sciences enters into exclusive distributor agreement for ILUVIEN in Italy, San Marino and Vatican City
M2 - Fri Aug 14, 5:30AM CDT
Pharmaceutical company Alimera Sciences (NasdaqGM:ALIM) Thursday launched an exclusive agreement for the distribution of ILUVIEN in Italy, San Marino and Vatican City.
ALIM: 2.61 (+0.04)
Alimera Sciences Limited Signs Exclusive ILUVIEN® Distributor for Italy, San Marino and Vatican City
PR Newswire - Thu Aug 13, 7:00AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Alimera Sciences Limited, its European subsidiary based in London, has signed an exclusive five-year agreement with Societa Industria Farmaceutica Italiana S.p.A. (SIFI), headquartered in Catania, Italy, for distribution of ILUVIEN® in Italy, San Marino and Vatican City. Under the terms of this agreement, SIFI will handle all promotion, marketing and commercial activities in those locations for ILUVIEN, Alimera's sustained release intravitreal injection for the treatment of diabetic macular edema.
ALIM: 2.61 (+0.04)
Alimera Sciences reports 2Q loss
Automated Insights - Mon Aug 10, 5:21PM CDT
ALPHARETTA, Ga. (AP) _ Alimera Sciences Inc. (ALIM) on Monday reported a second-quarter loss of $8.6 million, after reporting a profit in the same period a year earlier.
ALIM: 2.61 (+0.04)
Alimera Sciences Reports Second Quarter 2015 Financial Results
PR Newswire - Mon Aug 10, 3:06PM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the second quarter ended June 30, 2015.
ALIM: 2.61 (+0.04)
Sustained Release Ocular Drug Delivery Systems, 2015 - 2025
M2 - Wed Aug 05, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g2gzr3/sustained_release) has announced the addition of the "Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)" report to their offering. The Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)' report provides an extensive study of the emerging market of implants and particulate drug delivery systems (DDS) for ophthalmic diseases. The focus of this study is on commercial implants and those under development, their applications and the likely mid-term and long-term evolution. It is widely anticipated that such drug delivery systems have tremendous potential as they provide improved retention time compared to topical applications and offer convenience over regular intravitreal injections, mainly for posterior eye diseases. The report covers various aspects such as technological progress, product pipeline, target indications, industry and academic research programs to assess new evolving opportunities. We have provided a competitive spider web analysis to compare different implants based on technical parameters (drug elution rate, amount of drug delivered, life of implant etc.) and their likely user friendliness. Our opinion and insights, presented in this study, were influenced by the discussions that we conducted with different ophthalmic implant developers in this industry. The base year for the report is 2014. The report provides market forecasts for the following two time horizons: 2015 - 2020 and 2020 - 2025. In addition to the above, we have also provided our own independent perspective on the key drivers behind the growth of this market, likely challenges and potential threats. The research, analysis and insights presented in this report include the sales potential of various marketed and late stage pipeline ocular sustained drug delivery systemsbased on the current expected launch timelines, adoption rates and the estimated end-use price points.The figures mentioned in this report are in USD, unless otherwise specified. Highlights: - More than 25 companies are currently working on developing sustained release drug delivery systems for the treatment of ocular indications. Examples of some key players include pSivida, Allergan, Ocular Therapeutix, Neurotech Pharmaceuticals, Icon BioScience and GrayBug. - Vitrasert, launched in 1996, was the first ocular implant. It was, however, taken off the market in 2013. Only three more implants have received regulatory approval since 1996; these are Retisert, Ozurdex and Iluvien. - Majority of the systems (52%) are in preclinical stage of development. Over 10 systems are currently undergoing late stage clinical trial studies. Once approved, these inserts are likely to provide a major impetus to the overall market. - DME and Uveitis will provide the much needed boost to the sustained release ocular drug delivery systems market in the short-term. In the mid to long term, the growth will be fostered by launch of sustained release systems for glaucoma and AMD. In fact, more than 15 sustained release formulations are under development for the treatment of glaucoma. - Interest of venture capital firms, licensing/ partnership opportunities will continue to act as key growth drivers of this market. During our research, we identified several instances where venture capitalists and other strategic investors have actively supported the research efforts. - The overall market is likely to be more than USD 6.5 billion in the coming decade. The opportunity could be much higher in the outer years, especially driven by the regulatory approval of implants for delivery of biologics. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Market Overview 5. Product Profiles and Sales Forecast 6. Company Profiles 7. Venture Capital Support 8. Recent Partnerships 9. SWOT Analysis 10. Interview Transcripts 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List Of Companies Companies Mentioned - Partial List of Companies - 3i Plc - AbbVie - Abell Foundation - Aciont, Inc. - Actavis Plc - Aerie Pharmaceutical - Ain Shams University, Cairo, Egypt - Alcon - Alimera Sciences - Allergan - Alliance Medical Products Inc - Alpha Associates - Amgen Inc. - Amorphex Therapeutics - Apax Partners - Ascension Health Ventures - Atlas Venture - Auritec Pharmaceuticals - Avida Group - Bausch & Lomb - Baxter Venture - Bayer Healthcare - BCN Peptides - Ben Venue Laboratories - BioLight Israeli Life Sciences Investments Ltd. - Brandon Biosciences - Brecon Pharmaceuticals Ltd - Brown Advisory For more information visit http://www.researchandmarkets.com/research/g2...ed_release
AGN: 274.84 (-1.32), ALIM: 2.61 (+0.04), AMGN: 149.59 (-0.31), OCUL: 16.34 (+0.87)
Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results
PR Newswire - Thu Jul 30, 7:30AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its second quarter fiscal year 2015 financial results after the market close on Monday, August 10, 2015. An investor conference call will follow on the same day at 4:30 p.m. ET.
ALIM: 2.61 (+0.04)
Alimera Sciences enters into Canadian distribution agreement for ILUVIEN with Knight Therapeutics
M2 - Wed Jul 22, 5:08AM CDT
Pharmaceutical company Alimera Sciences (NasdaqGM:ALIM) revealed on Tuesday the launch of an exclusive agreement for the distribution in Canada of its sustained release intravitreal implant for the treatment of diabetic macular edema, ILUVIEN.
ALIM: 2.61 (+0.04)
Alimera Sciences Signs Knight Therapeutics as Exclusive ILUVIEN(R) Distributor for Canada
Marketwired - Tue Jul 21, 7:02AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"
, a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has signed an exclusive agreement with Knight Therapeutics Inc. (TSX: GUD) ("Knight" , a leading Canadian specialty pharmaceutical company, for the distribution in Canada of ILUVIEN(R), Alimera's sustained release intravitreal implant for the treatment of diabetic macular edema. Under the terms of this agreement, Knight will also handle all regulatory and commercial activities for ILUVIEN in Canada. ILUVIEN currently is not approved for sale in Canada. ALIM: 2.61 (+0.04), GUD.TO: 7.14 (-0.02)
Alimera Sciences Signs Knight Therapeutics As Exclusive ILUVIEN® Distributor For Canada
PR Newswire - Tue Jul 21, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"
, a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has signed an exclusive agreement with Knight Therapeutics Inc. (TSX: GUD) ("Knight" , a leading Canadian specialty pharmaceutical company, for the distribution in Canada of ILUVIEN®, Alimera's sustained release intravitreal implant for the treatment of diabetic macular edema. Under the terms of this agreement, Knight will also handle all regulatory and commercial activities for ILUVIEN in Canada. ILUVIEN currently is not approved for sale in Canada. ALIM: 2.61 (+0.04), GUD.TO: 7.14 (-0.02)
Dry (Atrophic) Macular Degeneration Therapeutics Pipeline Review, H1 2015 - 20 Companies & 29 Drug Profiles
M2 - Thu Jul 09, 9:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d36tg9/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Bioheart, Inc. - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Eleven Biotherapeutics Inc. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - Sun Pharma Advanced Research Company Ltd. Drug Profiles - AdipoCell - APL-2 - avacincaptad pegol sodium - EBI-028 - eculizumab - emixustat hydrochloride - fluocinolone acetonide - Gene Therapy for Ocular Diseases - GS-020 - GSK-933776 - HMR-59 - ICR-14967 - lampalizumab - MA09-hRPE - MC-1101 - methotrexate - minocycline Gel - NM-9405 - NT-501 - OpRegen - OpRegen Plus - RC-1 Alpha - Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - RST-001 - Small Molecules for Age Related Macular Degeneration - Small Molecules for AMD - Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - TT-231 For more information visit http://www.researchandmarkets.com/research/d3...y_atrophic
OCAT: 4.70 (+0.02), OPHT: 42.73 (+0.20), FOMX: 6.84 (+0.17), GSK: 40.22 (+0.06), ALIM: 2.61 (+0.04), ALXN: 161.08 (-3.23)
Alimera Sciences To Present At Cantor Fitzgerald Inaugural Healthcare Conference
PR Newswire - Mon Jun 29, 3:05PM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Rick Eiswirth, Chief Operating Officer and Chief Financial Officer, will present at the 2015 Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 at 8:00 a.m. ET at Le Parker Meridien Hotel in New York.
ALIM: 2.61 (+0.04)
BUYINS.NET: INTX, FIBK, PTM, BIP, AGNC, ALIM Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri May 29, 7:56AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Intersections Inc (NASDAQ:INTX), First Interstate Bancsystem Inc (NASDAQ:FIBK), Platinum Group Metals Ltd (NYSE
TM), Brookfield Infrastructure Partners LP (NYSE:BIP), American Capital Agency Corp (NASDAQ:AGNC), Alimera Sciences Inc (NASDAQ:ALIM) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: INTX: 2.01 (+0.06), ALIM: 2.61 (+0.04), BIP: 40.31 (unch), AGNC: 19.36 (-0.08), FIBK: 27.88 (-0.30), PTM: 10.56 (+0.37), PLG: 0.31 (+0.03)
Alimera Sciences Announces Presentation Time Change At UBS Global Healthcare Conference
PR Newswire - Mon May 18, 3:22PM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced a change in the Company's presentation time at this week's UBS Global Healthcare Conference in New York.
ALIM: 2.61 (+0.04)
Alimera Sciences To Present At UBS Global Healthcare Conference
PR Newswire - Mon May 11, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its management will present at the UBS Global Healthcare Conference in New York.
ALIM: 2.61 (+0.04)
